The clinical significance of soluble PD-1 and PD-L1 in lung cancer-Reference-Cited by-同舟云学术

The clinical significance of soluble PD-1 and PD-L1 in lung cancer

Published:2019-11 Issue: Volume:143 Page:148-152
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Abu Hejleh Taher,Furqan Muhammad,Ballas Zuhair,Clamon Gerald

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference31 articles.

1. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis;Aarslev;Scand. J. Gastroenterol.,2017

2. Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC;Antonia;N. Engl. J. Med.,2018

3. Heterogeneity of PD-L1 expression and relationship with biology of NSCLC;Bassanelli;Anticancer Res.,2018

4. Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: an interim analysis;Bonomi;Oncol. Lett.,2019

5. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines;Chen;Cytokine,2011

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint activity exacerbate renal interstitial fibrosis progression by enhancing PD-L1 expression in renal tubular epithelial cells;Translational Research;2024-09

2. Assessment of the Circulating PD-1 and PD-L1 Levels and P53 Expression as a Predictor of Relapse in Pediatric Patients with Wilms Tumor and Hypernephroma;Children;2024-08-23

3. Prognostic significance of soluble PD-L1 in prostate cancer;Frontiers in Immunology;2024-07-11

4. NF-κB in the Radiation Response of A549 Non-Small Cell Lung Cancer Cells to X-rays and Carbon Ions under Hypoxia;International Journal of Molecular Sciences;2024-04-19

5. CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line;Journal of Translational Medicine;2024-04-03